Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Most Read

  1. Genentech doses first patient in Perjeta and Herceptin Phase 3 study
  2. Combining antibiotics with immune response to treat antibiotic resistant bacteria
  3. May’s top news stories
  4. Algorithm optimises peptides to target drug-resistant bacteria
  5. Computer simulation offers digital penicillin production

Latest Content

Validated Metal Analysis

Four commonly utilized carbohydrates for ptotein stabilization are Sucrose, Trehalose, Mannitol, and Maltose.

Paradigm Shift Regarding API and Formulation Components

This whitepaper will provide an introduction to high-purity carbohydrates often used for applications such as stabilisation, modulation, and cryopreservation, comparing the old paradigm that formulation components are inactive ingredients with limited functionality with the new paradigm, which suggests these components play a significant role in therapeutic stability, quality, potency, immunogenicity, and bioavailability.

August’s top news stories

Gradalis started a Phase lll clinical trial of Vigil in combination with irinotecan and temozolomide for the treatment of patients with Ewing’s sarcoma, and Impel NeuroPharma dosed the first subject in the Phase l Safety and Tolerability of Intranasal POD-olanzapine (SNAP 101) trial of INP105. Drugdevelopment-technology.com wraps up the key news stories from August 2018.

Characterising Liposomes using Multi-Angle DLS

Liposomes are nowadays frequently used as drug delivery systems, and as such requires that they are well characterised for manufacturing and batch release. This characterisation includes their size and size distribution.

July’s top news stories

The Kyoto University’s Centre for iPS Cell Research and Application (CiRA) in Japan is to start two clinical trials that will evaluate human induced pluripotent stem cells (iPS) to treat Parkinson’s disease, and Critical Path Institute’s (C-Path) Critical Path for Parkinson’s Consortium (CPP), along with Parkinson’s UK, announced that the European Medicines Agency (EMA) issued a positive qualification opinion on biomarker as a tool to boost clinical trials on Parkinson’s. Drugdevelopment-technology.com wraps up the key news stories from July 2018.

Getting Acquainted with the Theory of XRF

This white paper provides a general introduction to X-ray Fluorescence (CRF) spectrometry and XRF analysis. It explains how a spectrometer works and how XRF analysis is achieved.

Genentech doses first patient in Perjeta and Herceptin Phase 3 study

Genentech has dosed the first patient in a Phase 3 study of a fixed-dose combination of pertuzumab (Perjeta) and trastuzumab (Herceptin) for subcutaneous administration using US-based biotechnology firm Halozyme's proprietary Enhanze drug-delivery technology in combination with chemotherapy.

Pre-Clinical and Clinical Studies in Dermatology

Monasterium Laboratory's pre-clinical research philosophy is to operate as much as possible with intact human hair follicles and skin, which are then exposed to test agents ex vivo (organ culture) or in vivo (human skin xenotransplants on SCID mice).

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top